Shares of Bellicum Pharmaceuticals (NASDAQ: BLCM) fell nearly 14% today after it filed two S-3 documents with the U.S. Securities and Exchange Commission yesterday afternoon. An S-3 is a registration form used to disclose certain activities that involve shares of a company’s common stock.